Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396242 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863883 (CHEMBL2176367) | ||
IC50 | 13±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396242 | |||
n/a | |||
Name | BDBM50396242 | ||
Synonyms: | CHEMBL2172309 | ||
Type | Small organic molecule | ||
Emp. Form. | C32H42FN5O3 | ||
Mol. Mass. | 563.706 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC[C@H]3C(C)(C)O)cc12 |r,wU:9.12,6.5,wD:34.37,(46.44,-26.96,;44.93,-26.64,;44.45,-25.18,;43.9,-27.79,;42.4,-27.47,;41.37,-28.62,;41.92,-26.01,;40.41,-25.69,;39.93,-24.23,;40.96,-23.08,;42.46,-23.39,;42.94,-24.86,;40.48,-21.62,;41.38,-20.36,;42.92,-20.35,;43.68,-19.01,;42.91,-17.69,;45.22,-19.01,;46,-20.33,;47.54,-20.33,;48.3,-18.99,;49.84,-18.97,;47.51,-17.65,;45.98,-17.67,;40.46,-19.11,;38.99,-19.6,;37.66,-18.84,;36.33,-19.61,;36.32,-21.15,;34.99,-21.92,;33.66,-21.15,;33.5,-19.62,;32,-19.3,;31.23,-20.63,;32.26,-21.78,;31.93,-23.28,;30.84,-24.37,;30.44,-22.87,;33.08,-24.31,;37.66,-21.92,;39,-21.15,)| | ||
Structure |